If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Regulatory News (GNS)

Share Price Information for Genus (GNS)

Share Price is delayed by 15 minutes
Get Live Data
2,290.00    -22.00 (-0.95%)
Bid:
2,290.00
Ask:
2,296.00
Spread: 6.00 (0.262%)
Market Cap: £1.52b
GNS Live PriceLast checked at - London Stock Exchange

Intraday Genus Share Chart

Director/PDMR Shareholding

22 Sep 2010 14:49

RNS Number : 1319T
Genus PLC
22 September 2010
 

22 September 2010

 

Genus plc

 

('Genus' or 'the Company')

 

Director/PDMR Shareholding

 

 

Genus announces that conditional nil-cost share options were granted under the Genus 2004 Performance Share Plan ("the Plan") today to Richard Wood, Chief Executive, as to 57,631 ordinary shares of 10 pence each in the Company ("Ordinary Shares"). These options are subject to performance conditions which relate to growth in the Company's earnings per share over a three year period and which trigger vesting on an incremental basis.

 

Genus further announces that of 154,639 Ordinary Shares that vested today in favour of Richard Wood, Chief Executive, under the Plan, 154,639 Ordinary Shares were today sold on behalf of Richard Wood at a price of 770 pence per Ordinary Share.

 

Richard Wood's direct shareholding in the Company stands at 60,856 Ordinary Shares which represents 0.102% of the issued share capital of the Company which is currently 59,678,535 Ordinary Shares. In addition, he remains the beneficial owner of 195,457 conditional nil-cost options under the Plan.

 

Genus also announces that of 34,364 Ordinary Shares that vested today in favour of Ian Biggs, Head of Global Product & Business Strategy, under the Plan, 34,364 Ordinary Shares were today sold on behalf of Ian Biggs at a price of 770 pence per Ordinary Share. Ian Biggs' direct shareholding in the Company stands at 3,375 Ordinary Shares which represents 0.006% of the issued share capital of the Company. In addition, he remains the beneficial owner of 109,530 conditional nil-cost options under the Plan.

 

Of 33,505 Ordinary Shares that vested today in favour of Thomas Philip Acton, Chief Operating Officer of Europe & The Far East, under the Plan, 33,505 Ordinary Shares were today sold on behalf of Thomas Philip Acton at a price of 770 pence per Ordinary Share.

Thomas Philip Acton's direct shareholding in the Company stands at 21,104 Ordinary Shares which represents 0.035% of the issued share capital of the Company. In addition, he remains the beneficial owner of 103,084 conditional nil-cost options under the Plan.

 

Of 17,182 Ordinary Shares that vested today in favour of Ian Farrelly, Group Company Secretary & General Counsel, under the Plan, 17,182 Ordinary Shares were today sold on behalf of Ian Farrelly at a price of 770 pence per Ordinary Share. Ian Farrelly has no direct shareholding in the Company. He remains the beneficial owner of 75,018 conditional nil-cost options under the Plan.

 

 

For further information please contact:

 

Cara Crichton

Company Secretarial Assistant

Genus plc

 

Tel: 01256 345996

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSUUSORRWAKUAR
Date   Source Headline
8th Sep 20165:18 pmRNSDirector/PDMR Shareholding
8th Sep 20167:00 amRNSPreliminary Results
7th Sep 20167:00 amRNSNON-EXECUTIVE DIRECTOR RETIREMENT
1st Sep 20164:17 pmRNSTotal Voting Rights
15th Aug 20167:00 amRNSFINAL JURY DECISIONS IN US LITIGATION
12th Aug 20167:00 amRNSFURTHER DECISIONS IN US LITIGATION
11th Aug 20167:00 amRNSFIRST DECISIONS IN US ANTI-TRUST LITIGATION
1st Aug 20169:20 amRNSBlock listing Interim Review
1st Aug 20169:09 amRNSTotal Voting Rights
27th Jul 20167:00 amRNSSigns exclusive licence for tech. to combat BRD
15th Jul 20167:00 amRNSAdoption of Financial Reporting Standard (FRS) 101
1st Jul 20163:10 pmRNSTotal Voting Rights
17th Jun 20164:40 pmRNSSecond Price Monitoring Extn
17th Jun 20164:35 pmRNSPrice Monitoring Extension
1st Jun 20162:00 pmRNSTotal Voting Rights
18th May 20167:00 amRNSExclusive Licence for Leading Gene Editing Tech
3rd May 20162:29 pmRNSTotal Voting Rights
13th Apr 20163:13 pmRNSDirector/PDMR Shareholding
1st Apr 20163:31 pmRNSDirector/PDMR Shareholding
9th Mar 20165:03 pmRNSDirector/PDMR Shareholding
4th Mar 20169:30 amRNSBOARD APPOINTMENT
3rd Mar 20162:00 pmRNSDirector/PDMR Shareholding
1st Mar 20165:17 pmRNSDirector/PDMR Shareholding
23rd Feb 20167:00 amRNSINTERIM RESULTS
1st Feb 20161:22 pmRNSBlocklisting Interim Review
4th Jan 20165:40 pmRNSTotal Voting Rights
11th Dec 20153:14 pmRNSDirector/PDMR Shareholding
9th Dec 20154:30 pmRNSDirector/PDMR Shareholding
8th Dec 20157:00 amRNSTackles major pig disease with breakthrough tech
1st Dec 20154:54 pmRNSHolding(s) in Company
1st Dec 20154:46 pmRNSTotal Voting Rights
19th Nov 20152:52 pmRNSResult of AGM
19th Nov 20157:00 amRNSAGM - TRADING UPDATE
2nd Nov 20153:04 pmRNSTotal Voting Rights
22nd Oct 20155:48 pmRNSHolding(s) in Company
21st Oct 20156:10 pmRNSDirector/PDMR Shareholding
15th Oct 201512:46 pmRNSAnnual Report and Notice of AGM
1st Oct 20153:00 pmRNSTotal Voting Rights
15th Sep 201511:00 amRNSDirector/PDMR Shareholding
8th Sep 20157:00 amRNSPreliminary Results
3rd Aug 20152:00 pmRNSBlocklisting Interim Review
30th Jun 20152:00 pmRNSTotal Voting Rights
29th Jun 20152:00 pmRNSChange of Registered Office
29th May 20152:00 pmRNSTotal Voting Rights
12th May 20157:00 amRNSCapital Markets Event and Trading Update
11th May 20152:00 pmRNSHolding(s) in Company
7th May 20152:21 pmRNSHolding(s) in Company
30th Apr 20152:00 pmRNSTotal Voting Rights
14th Apr 20152:00 pmRNSDirector/PDMR Shareholding
13th Apr 20155:06 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.